John A Bernat
3PUBLICATIONS
9CO-AUTHORS
Get your video featured.
Publish with JoVEGet your video featured.
Publish with JoVE
Publications (3)
Sort by Publication Date:
|Mar 21, 2026
Long-term efficacy and safety of pegunigalsidase alfa administered every 4 weeks in adults with Fabry disease: results from up to 5 years of the BRIGHT F51 phase III, open-label extension study.Myrl Holida, Aleš Linhart, Nicola Longo
|Jan 10, 2026
Lucerastat, an oral therapy for Fabry disease: results from a pivotal randomized phase 3 study and its open-label extension.Peter Nordbeck, Ozlem Goker-Alpan, John A Bernat
|Oct 09, 2024
A phase III, open-label clinical trial evaluating pegunigalsidase alfa administered every 4 weeks in adults with Fabry disease previously treated with other enzyme replacement therapies.Myrl Holida, Aleš Linhart, Antonio Pisani
Pageof 1
Frequent Collaborators
1 joint publications
Peter Nordbeck
1 joint publications
Dominique P Germain
1 joint publications
Pilar Giraldo
1 joint publications
Kathleen Nicholls
1 joint publications
Mark Thomas
1 joint publications
Michael L West
1 joint publications
Markus S Mueller
1 joint publications
Christoph Wanner
1 joint publications
Derralynn Hughes
